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ABSTRACT
Antiphospholipid antibodies (APA) are associated with thrombosis, thrombocytopenia and fetal
loss but they occur in a variety of diseases. Despite many efforts, a correlation between the speci-
ficity of particular subgroups of APA and particular clinical situations remains to be established.
The antigens at the origin of APA remain to be identified. We discuss here the possible links
between cell apoptosis or necrosis, leading to plasma membrane alterations, and the occurrence of
APA in response to sustained stimulation. The pathogenic potential ofAPA is also considered with
respect to recurrent pregnancy loss. Infec. Dis. Obstet. Gynecol. 5:176-180, 1997.
(C) 1997 Wiley-Liss, Inc.
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ROUTINE DETECTION OF
ANTIPHOSPHOLIPID ANTIBODIES
Antiphospholipid antibodies (APA) are frequently
detected in routine laboratory practice. Various tar-
gets are used in ELISA. However their reactivity is
highly heterogeneous. The different phospholipids
used are either negatively-charged, cardiolipin and
phosphatidylserine, or neutral like phosphatidyl-
ethanolamine, or mixtures. Concerning the protein
components of complex antigens, the importance
of [32-glycoprotein I and prothrombin is now widely
accepted. Some other phospholipid-binding pro-
teins like kininogens, protein C, protein S or an-
nexin V could also expose neoepitopes when
bound to phospholipids. 1,z Under certain in vitro
conditions, the presence of phospholipid is not
even required for APA binding to protein cofac-
tors.3 In vivo, it is certainly conceivable that phos-
pholipids are needed to present the proteins. APA
probably result from the reactivity of the immune
system to membrane components that are normally
sequestered in the absence of cell stimulation and/
or to plasma proteins showing a certain affinity for
such components when accessible. The different
modes of phospholipid exposure combined with
the binding of different proteins could explain the
heterogeneity of APA.
EXPOSURE OF SEQUESTERED
PHOSPHOLIPIDS
Cardiolipin (diphosphatidylglycerol), phosphati-
dylserine and phosphatidylethanolamine are the
most frequent phospholipids used as targets for
APA. Phosphatidylserine and phosphatidylethanol-
amine are ubiquitous aminophospholipid compo-
nents of eukaryotic cell plasma membranes. In
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resting cells, they are mostly restricted to the inner
leaflet of the membrane.4 The ability of phospha-
tidylethanolamine to adopt hexagonal phase orga-
nization could explain its immunogenicity, but the
physiopathological conditions allowing this confor-
mation are probably not frequent. Cardiolipin is
mainly localized in the inner membrane of the mi-
tochondria. A drastic lesion, due to mechanical
stresss or necrosis, is necessary to expose this phos-
pholipid. Apoptosis and necrosis, as well as inflam-
mation and infection, are cell death pathways and
clinical situations during which the loss of mem-
brane asymmetry is observed. Resting platelets,
monocytes, endothelial cells and red blood cells
present an asymmetric distribution of the phospho-
lipid constituents of their plasma membrane.
Stimulated cells, apoptotic ceils and bodies, shed
microparticles and necrotic fragments present
membrane rearrangements.
Aminophospholipids become exposed at the
outer surface of the plasma membrane of stimu-
lated cells and that of shed microparticles. The
most frequent example is that of platelets,4 but
monocytes
6 and endothelial cells7 are also able to
elicit a similar membrane response. Once acces-
sible to plasma vitamin K-dependent clotting fac-
tors, phosphatidylserine, in cooperation with phos-
phatidylethanolamine, acquires the ability to pro-
mote the assembly of the characteristic enzyme
complexes of the coagulation cascade.4 Different
clinical situations are associated with increased cir-
culating platelet microparticles.
8-13 One of them,
idiopathic thrombocytopenic purpura, is further
characterized by the three following observations:
APA positivity is a common feature in patients with
idiopathic thrombocytopenic purpura, 14 APA are
able to bind to platelet microparticles in idiopathic
thrombocytopenic purpura,
is and platelet micro-
particles in idiopathic thrombocytopenic purpura
are enriched in [32-glycoprotein I.6 This is cer-
tainly suggestive of the generation of APA in re-
sponse to an increase of platelet microparticles.
Inflammation is a common pathological situa-
tion in which increased aminophospholipid inside-
out migration and microparticle shedding are likely
to occur. Proinflammatory mediators, interleukin
1-13 and tumor necrosis factor-a, induce procoagu-
lant phospholipid exposure, increased thrombin
generation and subsequent or concomitant cell-cell
interactions. When combined, these effects result
in a dramatic augmentation of the thrombotic risk.
APA have been reported to inhibit procoagulant
activity of activated platelets and platelct-dcrived
microparticles. 17 Hence, two questions arise from
these considerations: do APA occur in response to
sustained exposure of thrombogenic phospholipid
surfaces?, and the corollary: are APA first synthe-
sized as ’protecting antibodies’?
The APA associated with infection have been
claimed to be 132-glycoprotein I-independent anti-
bodies and probably not related to thrombosis.
Nevertheless, it is not an easy task to discriminate
between these two different types of antibodies. In
bacteria, different membrane components such as
lipid A and cardiolipin are candidate targets for
APA. Concerning parasites, phosphatidylscrine ex-
pression at the surface of malaria-parasitized eryth-
rocytes is now well described. More data are avail-
able regarding viruses. Membrane rearrangements
occur during fusion and viral maturation of envel-
oped viruses. The envelope is a modified host cell
plasma membrane, is In all cases of infection,
complement-mediated cell lysis leads to inflamma-
tion and increased circulating cell fragments. The
association between hepatitis C virus and APA has
been studied in patients with hemophilia
19 and
HIV infection,e Furthermore, the increased rate of
thrombin generation in hepatitis C virus cirrhotic
patients,zl combined with the increased prevalence
of anticardiolipin antibodies in chronic hepatitis
C,zz suggests an implication of this virus in the as-
sociated antiphospholipid syndrome.
Exposure of phosphatidylserine at the surface of
apoptotic cells and derived fragments is an early
feature of apoptosis,e3,e4 Fadok et al. and other
groups demonstrated that phosphatidylserine trig-
gers recognition and removal by phagocyte.2s-27
The identity of phosphatidylserine receptor(s) re-
mains to be established but [32-glycoprotein I could
be involved, as it has been detected on rapidly-
cleared liposomes. 28 Apoptotic cells and bodies
have comparable procoagulant properties as acti-
vated platelets and shed microparticles which can
be counteracted by purified immunoglobulin G
from patients with APA syndrome. The procoagu-
lant potential of apoptotic cells and derived frag-
ments could lead to pathologic coagulation and
their immunologic potential could be responsible
for the generation of APA.29 Hence, APA are ex-
pected to occur in diseases known to be associated
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Fig. I. The possible contribution of programmed cell death (apoptosis) and necrosis in the occurrence of antiphospholipid
antibodies (APA). Phosphatidylserine and phosphatidylethanolamine are sequestered in the inner leaflet of the plasma mem-
brane of unstimulated cells. Cardiolipin is mainly found in the inner membrane of mitochondria. Hence, an apoptotic process
is expected to lead to phosphatidylserine and ’phosphatidylethanolamine externalization. In addition to these two lipids,
cardiolipin becomes accessible after cell necrosis.
with increased apoptosis such as AIDS, myocardial
infarction and stroke.3 Another situation of in-
creased apoptosis is alcoholic intoxication.
3 Che-
did et al. found that the prevalence of APA in-
creases dramatically in parallel with liver function
impairment.
31
Finally, it is important to emphasize the major
differences between apoptosis and necrosis. Apop-
tosis is induced by central cell death signal(s) or
survival factor deprivation and is characterized by
endonuclease activation, surface alterations and cy-
toskeletal reorganization. The different cell surface
alterations are as many triggers for removal by
phagocytes and, except when the reticuloendothe-
lial system is saturated, cell death and elimination
occur rapidly without inflammation. At the oppo-
site, necrosis is an acute cell injury accompanied by
leakage of cytoplasmic content and by the disinte-
gration of lysosomes and mitochondria which are
responsible for an inflammatory response.
3 Vari-
ous mechanisms including apoptosis and necrosis
could be responsible for APA generation, but, be-
cause of the associated inflammatory response, ne-
crosis could represent a true thrombotic risk. This
does not rule out the possible pathogenicity ofAPA
when synthesized in large excess (Figure 1).
A POSSIBLE THROMBOGENIC MECHANISM
AT THE ORIGIN OF PREGNANCY LOSS
Several pathogenic mechanisms have been pro-
posed to explain the association of APA with an
increased thrombotic risk,3z but none regarding a
possible interference of APA in pregnancy.
A recent contribution deserves particular atten-
tion regarding a possible mechanism of recurrent
fetal loss.33 These authors have evidenced the
presence of annexin V on placental villi and con-
firmed their observation on cultured trophoblasts
and endothelial cells. Owing to its strong affinity
for phosphatidylserine, annexin V, a protein whose
physiologic function remains to be established, ex-
erts a potent in vitro anticoagulant effect. Its asso-
ciation with the outer leaflet of the plasma mem-
brane of tissues fulfilling a barrier function may
originate from the active membrane remodeling oc-
curring in these cells. Aminophospholipid exposure
and microvesicle shedding result in the develop-
ment of procoagulant catalytic surfaces which have
to be neutralized. Annexin V, also translocated dur-
ing these membrane events, could precisely
achieve such an anticoagulant control. The inves-
tigators have observed that annexin V levels are
markedly reduced on placental villi from women
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presenting the antiphospholipid-antibody syn-
drome. In addition, they have shown that APA
from three patients who experienced repeated fetal
loss are able to displace annexin V from cultured
trophoblasts or endothelial cells. The reduction of
surface annexin V resulted in increased cell surface
procoagulant potential. This provides a rationale
for the recurrence of pregnancy loss.
CONCLUSIONPERSPECTIVES
The antiphospholipid-antibody syndrome may re-
flect cell damage at the origin of the so-called APA,
which in turn may acquire pathogenic potential de-
pending on special circumstances. The cellular al-
terations may lead to a thrombogenic phenotype
which has to be counteracted. Nevertheless, we are
left with an immunologic problem. Solutions
should be found in the light of the possible corre-
lation(s) between the presence of particular subsets
of APA and the occurrence of documented clinical
manifestations. This implies that APA are better
characterized at a molecular/gene level which
should help to explore their specificity towards bet-
ter defined antigens.
Because programmed cell death is of fundamen-
tal significance in embryogenesis and develop-
ment,
3 a challenging demonstration would be that
of an interference of APA in an apoptotic process
resulting in pregnancy loss or fetal growth retarda-
tion.
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